• Search

Search in Site

Industry news and analysis across pharma and medical devices PharmaDeviceNews.com

  • Home
  • Pharma & Biotech
  • Medical Devices & Diagnostics
  • Features & Analysis
  • Privacy Policy
  • About PharmaDeviceNews
  • Editorial Policy
  • Disclaimer
  • Contact Us
Home»Posts tagged with»Dana-Farber Cancer Institute

What TAG1’s Lead-212 supply deal with Dana-Farber reveals about the future of radiopharmaceutical oncology

By Pallavi Madhiraju on March 8, 2026   Pharma & Biotech  

What TAG1’s Lead-212 supply deal with Dana-Farber reveals about the future of radiopharmaceutical oncology

TAG1 and Dana-Farber partner to expand Lead-212 access for targeted alpha therapies. Discover what this means for radiopharmaceutical oncology innovation.

What the Akeso–INOVIO immunotherapy collaboration signals for the future of glioblastoma clinical research

By Pallavi Madhiraju on March 5, 2026   Pharma & Biotech  

What the Akeso–INOVIO immunotherapy collaboration signals for the future of glioblastoma clinical research

Akeso and INOVIO test cadonilimab plus INO-5412 in the INSIGhT glioblastoma trial. Explore what this immunotherapy strategy could mean for GBM research.

Why 10x Genomics is betting on CLIA lab certification to advance spatial diagnostics in oncology

By Pallavi Madhiraju on January 12, 2026   Medical Devices & Diagnostics  

Why 10x Genomics is betting on CLIA lab certification to advance spatial diagnostics in oncology

Find out how 10x Genomics and Dana-Farber aim to transform cancer diagnostics using spatial biology and single cell profiling for real-world clinical decisions.

Recent Posts

  • Can Zai Lab’s ZL-1503 turn dual-pathway itch control into a real atopic dermatitis advantage?
  • IntoDNA unveils sSTRIDE-NER and sSTRIDE-PARP1 at AACR 2026, can functional DNA repair assays reshape precision oncology?
  • Soley Therapeutics shows early tumor selectivity for STX-6398, but can CKAP2 modulation scale?
  • Akamis Bio AACR 2026 update: what early NG-350A data could mean for organ preservation
  • AACR 2026: SAGA Diagnostics pushes Pathlight MRD deeper into metastatic breast and ovarian cancer
  • Agenus AACR 2026 data show immune reprogramming signal in PD-1 refractory gastroesophageal cancer
  • AACR 2026: Can Zai Lab’s zocilurtatug pelitecan change the treatment picture for small cell lung cancer brain metastases?
  • How JANX014 expands Janux Therapeutics’ tumor-activated platform strategy in prostate cancer immunotherapy
  • What Medicus Pharma Ltd.’s SkinJect application signals for Hedgehog pathway-driven cancers
  • Why Bioxodes’ adaptive trial strategy could accelerate approval timelines in stroke therapeutics
  • What Kura Oncology’s latest data reveals about resistance biology in kidney cancer
  • Can Fate Therapeutics, Inc. solve the conditioning chemotherapy problem in CAR T?
    • About PharmaDeviceNews
    • Contact Us
    • Disclaimer
    • Editorial Policy
    • Privacy Policy
© 2026, ↑ PharmaDeviceNews
Log in - Powered by WordPress - Gabfire Themes